JPMorgan Chase & Co. reaffirmed their neutral rating on shares of Spire Healthcare Group (LON:SPI) in a research note issued to investors on Thursday. The brokerage currently has a GBX 339 ($4.53) price target on the stock.
Several other equities research analysts also recently issued reports on SPI. Jefferies Group decreased their price target on Spire Healthcare Group from GBX 350 ($4.68) to GBX 259 ($3.46) and set a hold rating for the company in a report on Monday, September 25th. Berenberg Bank reiterated a hold rating and set a GBX 270 ($3.61) price target on shares of Spire Healthcare Group in a report on Thursday, September 21st. Liberum Capital reiterated a hold rating and set a GBX 270 ($3.61) price target on shares of Spire Healthcare Group in a report on Thursday, November 16th. Finally, Numis Securities reiterated an add rating and set a GBX 350 ($4.68) price target on shares of Spire Healthcare Group in a report on Thursday, September 14th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. Spire Healthcare Group currently has an average rating of Hold and an average target price of GBX 309.86 ($4.14).
Shares of Spire Healthcare Group (LON SPI) opened at GBX 257.60 ($3.44) on Thursday. Spire Healthcare Group has a 1-year low of GBX 218.20 ($2.92) and a 1-year high of GBX 362.10 ($4.84). The stock has a market capitalization of $1,030.00 and a price-to-earnings ratio of 3,680.00.
In other Spire Healthcare Group news, insider Justin Ash acquired 84,500 shares of Spire Healthcare Group stock in a transaction on Thursday, November 23rd. The stock was purchased at an average price of GBX 237 ($3.17) per share, for a total transaction of £200,265 ($267,769.76). Also, insider Peter R. Bamford acquired 5,000 shares of Spire Healthcare Group stock in a transaction on Monday, November 27th. The stock was acquired at an average price of GBX 240 ($3.21) per share, with a total value of £12,000 ($16,044.93).
COPYRIGHT VIOLATION WARNING: This piece was reported by Equities Focus and is the property of of Equities Focus. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.equitiesfocus.com/2018/01/08/jpmorgan-chase-co-reiterates-neutral-rating-for-spire-healthcare-group-spi.html.
About Spire Healthcare Group
Spire Healthcare Group plc is a United Kingdom-based independent hospital group. The Company provides in-patient, daycase and out-patient care from approximately 40 hospitals, 10 clinics and over two specialist care centers across the United Kingdom. The Company also owns and operates a sports medicine, physiotherapy and rehabilitation brand, Perform, and a screening service, Lifescan, as well as national pathology services.
Receive News & Ratings for Spire Healthcare Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spire Healthcare Group and related companies with MarketBeat.com's FREE daily email newsletter.